WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 47.50
-1.34 (-2.74%)
Sep 10, 2026, 4:08 PM HKT
WuXi Biologics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8,904 | 9,214 | 8,279 | 9,670 | 6,395 | 9,003 |
Short-Term Investments | 3,521 | 5,587 | 1,907 | 340 | 304.47 | 1,148 |
Trading Asset Securities | 602.99 | 931.98 | 523.59 | 1,234 | 2,015 | 975.58 |
Cash & Short-Term Investments | 13,028 | 15,733 | 10,710 | 11,243 | 8,714 | 11,126 |
Cash Growth | 3.90% | 46.90% | -4.75% | 29.02% | -21.68% | 31.20% |
Accounts Receivable | 7,331 | 7,800 | 5,735 | 6,184 | 5,158 | 3,273 |
Other Receivables | 1,236 | 1,096 | 639.86 | 490.64 | 616.59 | 908.05 |
Receivables | 8,567 | 8,896 | 6,374 | 6,675 | 5,775 | 4,181 |
Inventory | 1,758 | 1,381 | 1,522 | 1,766 | 2,281 | 1,687 |
Other Current Assets | 3,844 | 2,126 | 4,967 | 1,514 | 1,700 | 2,535 |
Total Current Assets | 27,197 | 28,135 | 23,573 | 21,198 | 18,470 | 19,530 |
Property, Plant & Equipment | 31,562 | 29,754 | 28,435 | 29,939 | 25,916 | 19,756 |
Long-Term Investments | 3,031 | 3,203 | 2,400 | 2,934 | 2,709 | 2,203 |
Goodwill | 2,576 | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 |
Other Intangible Assets | 504.46 | 467.2 | 442.37 | 511.83 | 548.78 | 600.65 |
Long-Term Accounts Receivable | 46.3 | 50.77 | 85.67 | 165.5 | 109.17 | 124.49 |
Long-Term Deferred Tax Assets | 387.82 | 500.89 | 444.32 | 235.78 | 222.57 | 220.79 |
Other Long-Term Assets | 58.24 | 55.79 | 66.78 | 60.69 | 58.88 | 68.42 |
Total Assets | 65,363 | 63,697 | 56,977 | 56,576 | 49,564 | 44,033 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1,906 | 1,092 | 747.15 | 833.27 | 1,221 | 617.78 |
Accrued Expenses | 606.7 | 1,162 | 828.19 | 805.04 | 975.29 | 852.59 |
Current Portion of Long-Term Debt | 225.49 | 873.52 | 2,435 | 576.33 | 1,321 | 2,122 |
Current Portion of Leases | 415.86 | 381.95 | 183.7 | 154.98 | 149.06 | 103.56 |
Current Income Taxes Payable | 675.76 | 791.29 | 647.66 | 618.88 | 773.83 | 557.73 |
Current Unearned Revenue | 3,499 | 2,788 | 2,356 | 3,090 | 3,379 | 1,734 |
Other Current Liabilities | 861.55 | 1,220 | 1,423 | 1,558 | 1,499 | 2,268 |
Total Current Liabilities | 8,190 | 8,308 | 8,621 | 7,636 | 9,319 | 8,256 |
Long-Term Debt | 450.28 | 169.38 | 200.9 | 1,571 | 1,462 | 640.51 |
Long-Term Leases | 1,634 | 1,679 | 2,120 | 2,259 | 1,490 | 1,429 |
Long-Term Unearned Revenue | 347.44 | 341.08 | 460.47 | 969.23 | 949.46 | 876.73 |
Long-Term Deferred Tax Liabilities | 179.26 | 139.02 | 97.31 | 122.54 | 132.08 | 124.21 |
Other Long-Term Liabilities | 41.26 | 21.14 | - | - | - | - |
Total Liabilities | 10,842 | 10,657 | 11,500 | 12,558 | 13,351 | 11,326 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.23 | 0.23 | 0.23 | 0.24 | 0.23 | 0.24 |
Additional Paid-In Capital | - | 22,531 | 23,532 | 24,489 | 22,102 | 27,044 |
Retained Earnings | - | 23,242 | 18,334 | 14,978 | 11,578 | 7,158 |
Treasury Stock | - | - | - | -916.92 | - | -2,517 |
Comprehensive Income & Other | 48,070 | 1,476 | -46.54 | 1,782 | 1,367 | 593.13 |
Total Common Equity | 48,070 | 47,249 | 41,819 | 40,332 | 35,047 | 32,279 |
Minority Interest | 6,450 | 5,791 | 3,658 | 3,686 | 1,166 | 427.57 |
Shareholders' Equity | 54,521 | 53,039 | 45,478 | 44,018 | 36,213 | 32,706 |
Total Liabilities & Equity | 65,363 | 63,697 | 56,977 | 56,576 | 49,564 | 44,033 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2,726 | 3,104 | 4,940 | 4,561 | 4,422 | 4,295 |
Net Cash (Debt) | 10,303 | 12,629 | 5,770 | 6,682 | 4,293 | 6,831 |
Net Cash Growth | 38.61% | 118.87% | -13.65% | 55.66% | -37.16% | 32.68% |
Net Cash Per Share | 2.47 | 3.02 | 1.36 | 1.54 | 0.98 | 1.54 |
Filing Date Shares Outstanding | 4,143 | 4,134 | 4,106 | 4,223 | 4,225 | 4,224 |
Total Common Shares Outstanding | 4,143 | 4,134 | 4,106 | 4,223 | 4,225 | 4,224 |
Working Capital | 19,007 | 19,828 | 14,952 | 13,562 | 9,151 | 11,274 |
Book Value Per Share | 11.60 | 11.43 | 10.19 | 9.55 | 8.29 | 7.64 |
Tangible Book Value | 44,990 | 45,252 | 39,847 | 38,290 | 32,969 | 30,148 |
Tangible Book Value Per Share | 10.86 | 10.95 | 9.70 | 9.07 | 7.80 | 7.14 |
Land | - | 7,922 | 7,701 | 6,195 | 2,114 | 2,097 |
Machinery | - | 10,112 | 9,388 | 7,632 | 6,029 | 4,997 |
Construction In Progress | - | 10,600 | 9,755 | 13,750 | 15,935 | 10,873 |
Leasehold Improvements | - | 4,694 | 3,764 | 3,357 | 2,581 | 1,795 |
Order Backlog | - | 165,767 | - | - | - | 86,376 |